Nutriband Inc. Pioneers Abuse-Deterrent Drug Delivery System to Combat Opioid Crisis

Nutriband Inc. (NASDAQ: NTRB) is at the forefront of addressing the opioid crisis through its innovative abuse-deterrent drug delivery system, AVERSA technology. This technology is the foundation for the company's leading products, AVERSA Fentanyl and AVERSA Buprenorphine, which are designed to prevent the abuse and misuse of transdermal patches. AVERSA Fentanyl is poised to become the first opioid patch of its kind, with projected peak annual U.S. sales of $80 to $200 million. Similarly, AVERSA Buprenorphine is expected to achieve between $70 and $130 million in peak U.S. sales upon receiving approval.

The development of these products is a critical step forward in the fight against the opioid epidemic, a major public health challenge. Nutriband's approach combines abuse-deterrent science with transdermal innovation, filling a significant void in the pharmaceutical market. The scalability of the AVERSA platform not only facilitates the advancement of these two key products but also enhances Nutriband's potential for securing global patent protection. This underscores the wide-ranging applicability and significance of the company's technology in the pharmaceutical industry.

For further details on Nutriband's groundbreaking work, visit https://ibn.fm/8PgtJ.